James F. Howard, MD, discusses what he believes will be the next steps in treating myasthenia gravis.
James Howard, MD
Advertisement
Articles by James Howard, MD
James F. Howard, MD, discusses the significance of the FDA expanding the label for efgartigimod in patients with generalized myasthenia gravis (gMG).
A retrospective analysis of Medicare claims was used to study emergency department (ED) dispositions, specifically evaluating inpatient admissions compared with home health referrals.
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
Upcoming 2026 FDA Decisions Could Expand Treatment Options Across Oncology and Hepatitis B
2
Michigan Cyclospora Outbreak Surpasses 1500 Cases as Investigation Continues
3
Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies
4
FDA Approves Isatuximab On-Body Injector, Raising Anti-CD38 Competition in Myeloma
5